Aclarion projects no capital raises before key trial results, maintaining a cash runway into 2028 and focusing on shareholder value.
Quiver AI Summary
Aclarion, Inc., a healthcare technology company focused on chronic low back pain, announced that it expects no capital raises before significant upcoming catalysts. The company has a cash runway extending into 2028 and plans to report initial results from its 300-patient CLARITY trial by the end of Q3 2026, with public disclosure of interim results expected in Q4. With a strengthened financial position and a software-driven business model that enhances scalability and margin potential, Aclarion has discontinued its at-the-market (ATM) program and allowed its equity line of credit (ELOC) to expire, emphasizing its focus on driving value for shareholders. The company will increase its visibility among institutional healthcare investors and engage in clinical education in 2026. Aclarion's Nociscan platform utilizes advanced algorithms and biomarkers to assist physicians in identifying sources of pain in lumbar discs, offering a non-invasive diagnostic solution in the healthcare field.
Potential Positives
- Company has a cash runway into 2028, enabling it to complete its CLARITY trial without needing to raise additional capital.
- Aclarion's termination of its ATM and expiration of its ELOC reinforces its commitment to shareholder alignment and financial stability.
- Announcement of an upcoming initial readout of the CLARITY trial at the end of Q3 2026, with expected public disclosure of early interim results in Q4 2026, demonstrating imminent progress in their clinical development.
- Positioning as a software-native MedTech innovator highlights scalability, higher gross margins, and continuous improvement potential for its product, Nociscan.
Potential Negatives
- Company's termination of the ATM and expiration of the ELOC may limit future financing options if unexpected capital needs arise.
- The reliance on expected milestones like the CLARITY trial results introduces uncertainty; failure to meet these timelines could negatively impact investor confidence.
- Heavy focus on its software-native business model may not appeal to all investors, particularly those favoring traditional medical device companies.
FAQ
What is Aclarion's financial position heading into 2026?
Aclarion has a strengthened balance sheet with a cash runway into 2028, allowing completion of the CLARITY trial without raising additional capital.
When will Aclarion report results from the CLARITY trial?
The initial internal readout of the 300-patient CLARITY trial is expected at the end of Q3 2026, with early interim results in Q4.
What technology does Aclarion's Nociscan platform utilize?
Nociscan leverages Magnetic Resonance Spectroscopy and AI algorithms to help physicians noninvasively identify pain sources in lumbar discs.
Does Aclarion plan to raise capital after the CLARITY results?
Aclarion has no current plans for an ATM or ELOC until after reporting the initial interim results of the CLARITY trial.
How is Aclarion different from traditional medical device companies?
Aclarion operates as a software-native MedTech company, delivering solutions through the cloud, enabling scalability and improved algorithmic performance.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ACON Insider Trading Activity
$ACON insiders have traded $ACON stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ACON stock by insiders over the last 6 months:
- BRENT NESS (Chief Executive Officer) purchased 10 shares for an estimated $62
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ACON Revenue
$ACON had revenues of $18.9K in Q3 2025. This is an increase of 31.48% from the same period in the prior year.
You can track ACON financials on Quiver Quantitative's ACON stock page.
$ACON Hedge Fund Activity
We have seen 6 institutional investors add shares of $ACON stock to their portfolio, and 0 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DRW SECURITIES, LLC added 11,575 shares (+inf%) to their portfolio in Q3 2025, for an estimated $86,812
- CAPTRUST FINANCIAL ADVISORS added 10,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $75,000
- UBS GROUP AG added 1,050 shares (+inf%) to their portfolio in Q4 2025, for an estimated $4,830
- TOWER RESEARCH CAPITAL LLC (TRC) added 506 shares (+674.7%) to their portfolio in Q3 2025, for an estimated $3,795
- BNP PARIBAS FINANCIAL MARKETS added 230 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,725
- CITIGROUP INC added 1 shares (+inf%) to their portfolio in Q3 2025, for an estimated $7
- DANSKE BANK A/S added 0 shares (+0.0%) to their portfolio in Q4 2025, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ACON Analyst Ratings
Wall Street analysts have issued reports on $ACON in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Ascendiant Capital issued a "Buy" rating on 11/20/2025
To track analyst ratings and price targets for $ACON, check out Quiver Quantitative's $ACON forecast page.
Full Release
- Company anticipates no capital raises prior to expected value enhancing catalysts
- Cash runway into 2028
-
ATM terminated in early 2025 and ELOC expired December 31, 2025
BROOMFIELD, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the release of its 2026 Shareholder Letter from the Chairman. The letter outlines significant clinical, financial, and operational priorities as the company advances toward an expected initial internal readout of its 300-patient CLARITY trial at the end of Q3 and an expected public disclosure of early interim results in Q4 of 2026.
“Aclarion enters 2026 with a strengthened balance sheet, a scalable software-native business model, and a clear path to an initial readout on our CLARITY trial,” said Jeff Thramann, Executive Chairman of Aclarion. “With cash runway into 2028 and a clean capital structure, we are fully funded to deliver this important clinical milestone. Our focus is on ensuring that the value created by our early data accrues directly to our existing shareholders as we continue advancing a technology that provides physicians with objective biochemical insights to support better decision-making for patients suffering from chronic low back pain.”
The company highlighted its strengthened financial position. Following recent financings, the company reiterated it now has a cash runway into 2028, providing the resources needed to complete the CLARITY trial and operate through the initial data readout without raising additional capital. To reinforce this commitment to shareholder alignment, Aclarion no longer has an ATM in place and its ELOC expired at the end of 2025. The Company currently has 2,882,371 shares outstanding on a fully diluted basis and will not be putting a new ATM or ELOC in place until after it reports on the initial interim CLARITY results.
Aclarion also emphasized its position as part of a new generation of software-native MedTech innovators that, unlike traditional device companies, deliver its solution entirely through the cloud. This enables software-level gross margins, rapid scalability, and continuous algorithmic improvement without manufacturing or inventory constraints.
In 2026, the company will be executing a structured investor-awareness strategy focused on institutional healthcare investors, physician-led clinical education, and increased visibility in financial and medical media.
The full 2026 Shareholder Letter is available on the company’s website at: https://investors.aclarion.com/news
For more News from Aclarion, please visit: Latest News
To find a Nociscan center, view our site map here .
For more information on Nociscan, please email: [email protected]
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com .
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the enrollment of patients in our ongoing clinical trials, the expected initial internal readout of its 300-patient CLARITY trial at the end of Q3 2026 and an expected public disclosure of early interim results in Q4 of 2026, having a cash runway into 2028, providing the resources needed to complete the CLARITY trial and operate through the initial data readout without raising additional capital, the Company will not be putting a new ATM or ELOC in place until after it reports on the initial interim CLARITY results, the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
[email protected]
Media Contacts:
Jessica Starman
[email protected]
